Chronic Myeloid Leukemia Market Report provides a detailed analysis of the Chronic Myeloid Leukemia Market Size, Epidemiology, Drug therapies, Companies and pipeline for study period from 2019-2032.

Chronic Myeloid Leukemia Market Size, Share | Chronic Myeloid Leukemia Market Report, Market trends

1. Report Introduction
2. Executive Summary of Chronic Myeloid Leukemia (CML)
3. Chronic Myeloid Leukemia Market Share at a Glance
3.1. Seven Major Market Size of Chronic Myeloid Leukemia in 2019
3.2. Seven Major Market Size of Chronic Myeloid Leukemia in 2032
4. Disease Background and Overview
4.1. Causes
4.2. Signs and symptoms
4.3. Pathophysiology
4.4. Risk Factors
4.5. Diagnosis
5. Patient journey
6. Epidemiology and Patient Population
6.1. Assumptions and Rationale
6.2. Total Incident Cases of CML in the 7MM (2019&ndash;2032)
6.3. Total Symptomatic Cases of CML in the 7MM (2019&ndash;2032)
6.4. Cases of CML by Phases (Chronic, Accelerated, and Blast) in the 7MM (2019&ndash;2032)
6.5. Age-specific Cases of CML in the 7MM (2019&ndash;2032)
6.6. Mutation-specific cases of CML in the 7MM (2019&ndash;2032)
7. Country Wise: Epidemiology of Chronic Myeloid Leukemia
7.1. The United States
7.1.1. Assumptions and Rationale
7.1.2. Total Incident Cases of CML in the United States (2019&ndash;2032)
7.1.3. Total Symptomatic Cases of CML in the United States&nbsp; (2019&ndash;2032)
7.1.4. Cases of CML by Phases (Chronic, Accelerated, and Blast) in the United States&nbsp; (2019&ndash;2032)
7.1.5. Age-specific Cases of CML in the United States&nbsp; (2019&ndash;2032)
7.1.6. Mutation-specific cases of CML in the United States&nbsp; (2019&ndash;2032)
7.2. The EU-5 Epidemiology (Germany, France, Italy, Spain and the United Kingdom)
7.2.1. Total Incident Cases of CML in the EU-5 (2019&ndash;2032)
7.2.2. Total Symptomatic Cases of CML in the EU-5 (2019&ndash;2032)
7.2.3. Cases of CML by Phases (Chronic, Accelerated, and Blast) in the EU-5 (2019&ndash;2032)
7.2.4. Age-specific Cases of CML in the EU-5 (2019&ndash;2032)
7.2.5. Mutation-specific cases of CML in the EU-5 (2019&ndash;2032)
7.3. Japan
7.3.1. Total Incident Cases of CML in Japan (2019&ndash;2032)
7.3.2. Total Symptomatic Cases of CML in Japan (2019&ndash;2032)
7.3.3. Cases of CML by Phases (Chronic, Accelerated, and Blast) in Japan (2019&ndash;2032)
7.3.4. Age-specific Cases of CML in Japan (2019&ndash;2032)
7.3.5. Mutation-specific cases of CML in Japan (2019&ndash;2032)
8. Current Treatment and Medical Practices
8.1. Treatment Algorithm
8.2. Guidelines and Recommendations for Treatment of Chronic Myeloid Leukemia
8.2.1. United States
8.2.2. Europe
8.2.3. Japan
9. Marketed Drugs
9.1. SCEMBLIX (Asciminib): Novartis
9.1.1. Product Description
9.1.2. Regulatory Milestones
9.1.3. Advantages &amp; Disadvantages
9.1.4. Product Profile
9.1.5. Safety and Efficacy
9.1.6. Side effects
9.2. Bosulif (Bosutinib): Pfizer
9.2.1. Product Description
9.2.2. Regulatory Milestones
9.2.3. Advantages &amp; Disadvantages
9.2.4. Product Profile
9.2.5. Safety and Efficacy
9.2.6. Side effects
9.3. GLEEVEC (Imatinib): Novartis
9.3.1. Product Description
9.3.2. Regulatory Milestones
9.3.3. Advantages &amp; Disadvantages
9.3.4. Product Profile
9.3.5. Safety and Efficacy
9.3.6. Side effects
To be continued in the report...
10. Unmet Needs of Chronic Myeloid Leukemia
11. Emerging Therapeutics
11.1. Key Cross Competition
11.2. HQP1351: Ascentage Pharma
11.2.1. Regulatory Milestones
11.2.2. Clinical Development
11.2.3. Product Profile
11.2.4. Clinical Pipeline Activity
11.2.5. Ongoing Trials Information
11.2.6. Clinical Trial by Phase
11.3. ELVN-001: Enliven Therapeutics
11.3.1. Regulatory Milestones
11.3.2. Clinical Development
11.3.3. Product Profile
11.3.4. Clinical Pipeline Activity
11.3.5. Ongoing Trials Information
11.3.6. Clinical Trial by Phase
11.4. TERN-701: Terns Pharmaceuticals
11.4.1. Regulatory Milestones
11.4.2. Clinical Development
11.4.3. Product Profile
11.4.4. Clinical Pipeline Activity
11.4.5. Ongoing Trials Information
11.4.6. Clinical Trial by Phase
11.5. Navtemadlin: Kartos Therapeutics
11.5.1. Regulatory Milestones
11.5.2. Clinical Development
11.5.3. Product Profile
11.5.4. Clinical Pipeline Activity
11.5.5. Ongoing Trials Information
11.5.6. Clinical Trial by Phase
To be continued in the report...
12. Market Size of Chronic Myeloid Leukemia (CML)
12.1. Total 7MM Chronic Myeloid Leukemia Market Size (2019&ndash;2032)
12.2. Total 7MM Chronic Myeloid Leukemia Market Size by Therapies (2019&ndash;2032)
13.1. The United States
13.1.1. Total Market Size of Chronic Myeloid Leukemia in the United States
13.1.2. Total Market Size of Chronic Myeloid Leukemia by Therapies in the United States
13.2. The EU-5
13.2.1. Total Market Size of Chronic Myeloid Leukemia in the EU-5
13.2.2. Total Market Size of Chronic Myeloid Leukemia by Therapies in the EU-5
13.3. Japan
13.3.1. Total Market Size of Chronic Myeloid Leukemia in Japan
13.3.2. Total Market Size of Chronic Myeloid Leukemia by Therapies in Japan
14. Unmet Needs
15. SWOT Analysis
16. Reimbursement and Market access
17. Appendix
18. Report Methodology
18.1. Bibliography
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
*The Tables of Content is not exhaustive, will be provided in the final report.

Chronic Myeloid Leukemia Market

Chronic Myeloid Leukemia - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight's Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an insight of the Chronic Myeloid Leukemia market trends in 7MM.